The European Medicines Agency (EMA) Has Approved an Additional Subcutaneous Administration Option for TAKHZYRO ® (lanadelumab) for Patients Aged 12 Years and Above with Recurrent Attacks of Hereditary

The European Medicines Agency (EMA) Has Approved an Additional Subcutaneous Administration Option for TAKHZYRO ® (lanadelumab) for Patients Aged 12 Years and Above with Recurrent Attacks of Hereditary

Source link

What's Hot

Empire Media Named Toronto Tribune’s Marketing Agency of the Year for 2026

Snow-covered parking garage in Ottawa partially collapses, vehicles trapped

Trudeau to meet premiers as Trump tariff uncertainty continues – National

The European Medicines Agency (EMA) Has Approved an Additional Subcutaneous Administration Option for TAKHZYRO ® (lanadelumab) for Patients Aged 12 Years and Above with Recurrent Attacks of Hereditary

Madrigal Announces New Two-Year Data from the Compensated MASH Cirrhosis Arm of the MAESTRO-NAFLD-1 Trial Demonstrating Potential Benefit of Rezdiffra™ (resmetirom) in Patients with Compensated MASH

SILVER ONE PROVIDES UPDATE ON METALLURGICAL TEST RESULTS USING INNOVATIVE SEPARATION AND LEACHING TECHNOLOGIES AT ITS CANDELARIA SILVER MINE, NEVADA

Leafbuyer Technologies, Inc. Announces Record Results: 20% Increase in Quarterly Revenue, 68% Increase in Gross Margins and 134% Increase in Net Income

ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Integral Ad Science Holding Corp. Investors to Secure Counsel Before Important Deadline in Securities Class Action – IAS

ERCOT Board approves moving ahead to finalize CenterPoint Energy's emergency generation proposal; Company's actions will lower bills for Houston-area customers and help avoid regional energy shortfall

ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Innovative Industrial Properties, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – IIPR

What's Hot

The European Medicines Agency (EMA) Has Approved an Additional Subcutaneous Administration Option for TAKHZYRO ® (lanadelumab) for Patients Aged 12 Years and Above with Recurrent Attacks of Hereditary

Keep Reading

Subscribe to Updates